Compare POWL & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | POWL | PRAX |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.3B |
| IPO Year | 1995 | 2020 |
| Metric | POWL | PRAX |
|---|---|---|
| Price | $193.30 | $260.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $280.00 | ★ $644.42 |
| AVG Volume (30 Days) | ★ 470.9K | 441.7K |
| Earning Date | 11-17-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $448,716,000.00 | N/A |
| Revenue This Year | $7.85 | N/A |
| Revenue Next Year | $24.54 | $39,458.00 |
| P/E Ratio | $49.68 | ★ N/A |
| Revenue Growth | ★ 13.34 | N/A |
| 52 Week Low | $167.31 | $50.56 |
| 52 Week High | $612.50 | $392.70 |
| Indicator | POWL | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 27.51 |
| Support Level | $180.98 | $238.77 |
| Resistance Level | $219.27 | $337.47 |
| Average True Range (ATR) | 7.44 | 13.90 |
| MACD | 1.43 | -1.34 |
| Stochastic Oscillator | 48.22 | 2.21 |
Powell Industries Inc is a United States-based company that develops, designs, manufactures, and services custom-engineered equipment and systems for electrical energy distribution, control, and monitoring. The company's principal products comprise integrated power control room substations, custom-engineered modules, electrical houses, traditional and arc-resistant distribution switchgear and control gear, and so on. These products are applied in oil and gas refining, offshore oil and gas production, petrochemical, pipeline, terminal, mining and metals, light-rail traction power, electric utility, pulp and paper, and other heavy industrial markets. The company generates the majority of its sales from the United States, and the rest from Canada, Europe, Asia Pacific, and other regions.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.